Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2011-005189-39
    Sponsor's Protocol Code Number:11-10
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Temporarily Halted
    Date on which this record was first entered in the EudraCT database:2012-12-10
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2011-005189-39
    A.3Full title of the trial
    A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2-positive metastatic breast cancer
    Estudio aleatorizado fase III de TH (paclitaxel y trastuzumab) en comparación con THL (paclitaxel, trastuzumab y lapatinib) en el tratamiento de primera línea del cáncer de mama metastásico positivo para HER2.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2-positive metastatic breast cancer
    Estudio aleatorizado fase III de TH (paclitaxel y trastuzumab) en comparación con THL (paclitaxel, trastuzumab y lapatinib) en el tratamiento de primera línea del cáncer de mama metastásico positivo para HER2.
    A.3.2Name or abbreviated title of the trial where available
    TH v THL
    A.4.1Sponsor's protocol code number11-10
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorICORG
    B.1.3.4CountryIreland
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGlaxoSmithKline
    B.4.2CountryIreland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationICORG
    B.5.2Functional name of contact pointMarzena Wieczorkowska
    B.5.3 Address:
    B.5.3.1Street Address60 Fitzwilliam Square
    B.5.3.2Town/ cityDublin
    B.5.3.3Post codeDublin 2
    B.5.3.4CountryIreland
    B.5.4Telephone number0035316677211
    B.5.5Fax number0035316697869
    B.5.6E-mailmarzena.wieczorkowska@icorg.ie
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Tyverb
    D.2.1.1.2Name of the Marketing Authorisation holderGlaxo Group Limited
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLapatinib
    D.3.2Product code GW572016
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLAPATINIB
    D.3.9.1CAS number 231277-92-2
    D.3.9.4EV Substance CodeSUB25379
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number250
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Herceptin®
    D.2.1.1.2Name of the Marketing Authorisation holderROCHE REGISTRATION LIMITED
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTRASTUZUMAB
    D.3.9.1CAS number 180288-69-1
    D.3.9.4EV Substance CodeSUB12612MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/kg milligram(s)/kilogram
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePaclitaxel
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPACLITAXEL
    D.3.9.1CAS number 33069-62-4
    D.3.9.4EV Substance CodeSUB09583MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/m2 milligram(s)/square meter
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number80
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    HER 2 - positive metastatic breast cancer
    Cáncer de mama metastásico HER 2 positivo.
    E.1.1.1Medical condition in easily understood language
    HER 2 - positive metastatic breast cancer
    Cáncer de mama metastásico HER 2 positivo.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level PT
    E.1.2Classification code 10055113
    E.1.2Term Breast cancer metastatic
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare the efficacy of THL versus TH in first line treatment of metastatic HER2 positive breast cancer
    Comparar la eficacia de THL en comparación con TH en el tratamiento de primera línea del cáncer de mamametastásico positivo para HER2
    E.2.2Secondary objectives of the trial
    1. To examine the objective tumour response rate and overall survival of lapatinib with trastuzumab and paclitaxel compared to the paclitaxel and trastuzumab alone.
    2. To assess the safety and tolerability of lapatinib when administered with both paclitaxel and trastuzumab compared to the combination of paclitaxel and trastuzumab.
    3. To examine the effects of the TH regimen versus the THL regimen on health-related quality of life using the FACT-B questionnaire
    4. To examine the correlation between EGFR, HER2, HER3, Akt, and other potential biomarkers downstream of the EGFR and HER2 receptors in tumour tissue, where available
    5. To examine the correlation between serum concentrations of HER2 Extracellular Domain (ECD) and tumour response.
    6. To examine the correlation between circulating mRNAs and miRNAs in patient sera and tumour response.
    7. To determine if prophylactic Loperamide significantly reduces the number of diarrhoea-related adverse events.
    1.Tasa de respuesta tumoral objetiva y la supervivencia global de lapatinib con trastuzumab y paclitaxel en comparación con paclitaxel y trastuzumab solos.
    2.Evaluar la seguridad y tolerabilidad de lapatinib cuando se administra con paclitaxel y trastuzumab en comparación con la combinación de paclitaxel y trastuzumab.
    3.Examinar los efectos del tratamiento de TH en comparación con THL sobre la calidad de vida relacionada con la salud por medio del cuestionario FACT-B.
    4.Examinar la correlación entre EGFR, HER2, HER3, Akt, y otros posibles biomarcadores implicados en las rutas de señalización de los receptores EGFR y HER2 en el tejido tumoral, si estuviera disponible.
    5.Examinar la correlación entre las concentraciones séricas del dominio extracelular (DEC) de HER2 y la respuesta tumoral.
    6.Examinar la correlación entre los ARNm y miARN circulantes enel suerode las pacientes y la respuesta tumoral.
    7.Determinar si loperamida profiláctica reduce de manera significativa el núm...
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Written informed consent obtained prior to any study-related procedures
    2. Female age 18 years or greater.
    3. ECOG Performance Status of 0 or 1.
    4. Histologically or cytologically-confirmed invasive metastatic breast cancer.
    5. Patients must have measurable disease according to RECIST criteria Version 1.1, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >20 mm with conventional techniques or as >10 mm with spiral CT scan,MRI, or calipers by clinical exam.
    6. Tumour shows HER2 over-expression (3+ by IHC and/or FISH + ) by testing of the primary tumour and if available the biopsied metastatic lesion
    7. Patients who received prior radiotherapy must have completed it at least 4 weeks before registration and recovered from all treatment-related toxicities.
    8. Cardiac ejection fraction within the institutional range of normal as measured by MUGA or ECHO within 14 days prior to registration. Note that baseline and on treatment scans should be performed using the same modality and preferably at the same institution.
    9. Adequate haematological, hepatic, and renal function.
    ? Haemoglobin ? 9g/dL
    ? Neutrophils (ANC/AGC) ?1500/mm³ (1.5 x 10^9/L)
    ? Platelets ? (100 x 10^9/L)
    ? Total bilirubin ? 1.5mg/dL (25.65 ?mol/L)
    ? Both ALT (SGPT) and AST (SGOT) ? 3 x ULN with or without liver Metastasis
    ? Alkaline phosphatase ? 2.5 x ULN
    ? Serum creatinine ?1.5 ULN or calculated creatinine clearance (CrCl) ? 30mL/min according to the Cockcroft and Gault formula (Appendix K)
    10. Able to swallow and retain oral medication.
    11. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Female patients of childbearing potential must have pregnancy excluded by urine or serum beta-HCG testing within 7 days prior to registration.
    12. Estimated life expectancy greater than 12 weeks
    1. Consentimiento informado por escrito obtenido antes de cualquier procedimiento relacionado con el estudio
    2. Mujer de 18 años de edad en adelante.
    3. Estado funcional según ECOG de 0 o 1.
    4. Cáncer de mama metastásico invasivo confirmado mediante histología o citología.
    5. Las pacientes deben tener enfermedad medible conforme a los criterios RECIST Versión 1.1 definida al menos como una lesión que se puede medir de forma precisa en al menos una dimensión (en las lesiones no ganglionares se debe registrar el diámetro mayor y en las lesiones ganglionares, el eje corto) como > 20 mm con técnicas convencionales o como > 10 mm con TC helicoidal, RMN o compases calibradores mediante exploración clínica.
    6. El tumor debe mostrar sobreexpresión de HER2 (3+ mediante IHQ y/o FISH +) mediante la realización de las pruebas en el tumor primario y, si está disponible, en la lesión metastásica biopsiada.
    7. Las pacientes que hayan recibido radioterapia previa deben haberla completado al menos 4 semanas antes de la inclusión y haberse recuperado de todas las toxicidades relacionadas con el tratamiento.
    8. Fracción de eyección cardiaca dentro del intervalo institucional normal medido mediante MUGA o ecocardiograma en los 14 días previos a la inclusión. Tenga en cuenta que las exploraciones que se hagan al inicio o durante el tratamiento se deben realizar con la misma modalidad y preferentemente en la misma institución.
    9. Funciones hematológicas, hepáticas y renales adecuadas.
    ? Hemoglobina? 9g/dL
    ? Neutrófilos (ANC/AGC) ?1.500/mm³ (1.5 x 10^9/L)
    ? Plaquetas ? (100 x 10^9/L)
    ? Bilirrubina total ? 1.5mg/dL (25.65 ?mol/L)
    ? Tanto ALT (SGPT) como AST (SGOT) ? 3 x ULN con o sin metástasis hepática
    ? Fosfatasa alcalina ? 2,5 x LSN
    ? Creatinina sérica ?1,5 LSN o aclaramiento de creatinina calculado (CrCl) ? 30 mL/min según la fórmula de Cockcroft y Gault (Anexo K)
    10. Capacidad de tragar y retener la medicación por vía oral.
    11. Las mujeres en edad fértil deben aceptar el uso de un anticonceptivo adecuado (método de control de la natalidad hormonal o de barrera o abstinencia) antes de su entrada en el estudio y durante toda su participación. Las pacientes en edad fértil deben descartar el embarazo mediante una prueba de detección de beta-HCG en orina o sérico en realizada en los 7 días previos a la inclusión.
    12. Esperanza de vida estimada superior a 12 semanas
    E.4Principal exclusion criteria
    1. Prior systemic therapy for metastatic disease (except one line of hormonal therapy for metastatic disease without trastuzumab).
    2. Recurrence within 12 months from completion of adjuvant chemotherapy to the development of metastatic disease.
    3. Recurrence within 6 months from completion of adjuvant trastuzumab to the development of metastatic disease.
    4. Prior lapatinib treatment.
    5. Peripheral neuropathy ? grade 2
    6. Patients with known CNS metastasis should be excluded from this clinical trial
    7. Prior radiotherapy to more than half of the bony pelvis.
    8. Uncontrolled or symptomatic angina, uncontrolled arrhythmias, congestive heart failure, a documented MI within 6 months prior to registration or any other cardiac disorders, which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient .
    9. Immediate or delayed hypersensitivity or untoward reaction to paclitaxel, trastuzumab, or other related compounds, or to drugs chemically related to lapatinib (including other anilinoquinazolines, e.g. gefitinib (Iressa®) and erlotinib (Tarceva®), or other chemically-related compounds).
    10. Pregnant or breastfeeding women are excluded from this study.
    11. Patients should not be receiving any other investigational agents (within 30 days prior to registration) or receiving concurrent anticancer therapy.
    12. Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors (Table 9).
    13. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
    14. Patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn?s, ulcerative colitis).
    15. Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
    16. Concurrent treatment with ovarian hormone replacement therapy. Prior treatment must be stopped prior to registration.
    1. Tratamiento sistémico previo para enfermedad metastásica (excepto una línea de tratamiento hormonal para enfermedad metastásica sin trastuzumab).
    2. Recidiva en el plazo de 12 meses desde el fin de la quimioterapia adyuvante hasta la aparición de la enfermedad metastásica.
    3. Recidiva en el plazo de 6 meses desde el fin de trastuzumab adyuvante hasta la aparición de la enfermedad metastásica.
    4. Tratamiento previo con lapatinib.
    5. Neuropatía periférica ? grado 2
    6. Se debe excluir de este ensayo clínico a las pacientes con metástasis conocida en el SNC
    7. Radioterapia previa en más de la mitad de la pelvis ósea.
    8. Angina de pecho sintomática incontrolada, arritmias incontroladas, insuficiencia cardiaca congestiva, IM documentado en los 6 meses previos a la inclusión o cualquier otro trastorno cardiaco que, en opinión del médico que trata a la paciente, haría que este protocolo resultara excesivamente peligroso para la paciente.
    9. Hipersensibilidad inmediata o retardada o reacción adversa a paclitaxel, trastuzumab u otros compuestos relacionados, o a fármacos químicamente relacionados con lapatinib (incluidas otras anilinoquinazolinas, p. ej., gefinitib (Iressa®) y erlotinib (Tarceva®), u otros compuestos químicamente relacionados.
    10. Quedan excluidas de este estudio las mujeres embarazadas o en periodo de lactancia.
    11. Las pacientes no deben estar recibiendo ningún otro producto en investigación (en los 30 días previos a su inclusión) ni ningún tratamiento antineoplásico concurrente.
    12. Requisito concomitante de medicamentos clasificados como inductores o inhibidores del CYP3A4 (Tabla 9).
    13. Enfermedad intercurrente incontrolada, incluida, pero no limitada a, infecciones activas o en curso, o enfermedades psiquiátricas o situaciones sociales que limiten el cumplimiento de los requisitos del estudio.
    14. Pacientes con enfermedad del tracto gastrointestinal que cause incapacidad para tomar los fármacos por vía oral, síndrome de intolerancia, necesidad de alimentación por vía iv, procedimientos quirúrgicos previos que afecten a la absorción, enfermedad digestiva inflamatoria incontrolada (p. ej., enfermedad de Crohn, colitis ulcerosa).
    15. Enfermedad biliar o hepática actualmente activa (con excepción de las pacientes con síndrome de Gilbert, litiasis biliar asintomática, metástasis hepáticas o hepatopatía crónica estable según la evaluación del investigador)
    16. Tratamiento concomitante con terapia de sustitución hormonal ovárica. Los tratamientos previos se deben suspender antes de la inclusión.
    E.5 End points
    E.5.1Primary end point(s)
    1. The primary efficacy endpoint is progression free survival (PFS)
    1. La variable primaria de eficacia es la supervivencia libre de progresión (SLP).
    E.5.1.1Timepoint(s) of evaluation of this end point
    progression free survival (PFS)
    Supervivencia libre de progresión (SLP).
    E.5.2Secondary end point(s)
    1. Objective tumour response rate
    2. Overall survival
    3. To assess the safety and tolerability of lapatinib when administered with both paclitaxel and trastuzumab compared to the combination of paclitaxel and trastuzumab. Toxicities will be recorded and graded according to the NCI - CTCAE criteria, version 4
    4. Health-related quality of life as measured by the FACT-B questionnaire
    5. Correlation between EGFR, HER2, HER3, Akt, and other potential biomarkers downstream of the EGFR and HER2 receptors in tumour tissue, where available.
    6. Correlation between serum concentrations of HER2 ECD and tumour response.
    7. Correlation between circulating mRNAs and miRNAs in patient sera and tumour response.
    8. To determine if prophylactic loperamide significantly reduces the number of diarrhoea-related AEs.
    1. Tasa de respuesta tumoral objetiva
    2. Supervivencia global
    3. Evaluar la seguridad y tolerabilidad de lapatinib cuando se administra con paclitaxel y trastuzumab en comparación con la combinación de paclitaxel y trastuzumab. Las toxicidades se registrarán y clasificarán según los criterios NCI - CTCAE, versión 4
    4. Calidad de vida relacionada con la salud medida por el cuestionario FACT-B
    5. Correlación entre EGFR, HER2, HER3, Akt, y otros posibles biomarcadores implicados en las rutas de señalización de los receptores EGFR y HER2 en el tejido tumoral, si estuviera disponible.
    6. Correlación entre las concentraciones séricas del DEC de HER2 y la respuesta tumoral.
    7. Correlación entre los ARNm y miARN circulantes en suero de las pacientes y la respuesta tumoral.
    8. Determinar si loperamida profiláctica reduce de manera significativa el número de acontecimientos adversos relacionados con la diarrea.
    E.5.2.1Timepoint(s) of evaluation of this end point
    - Objective tumour response rate
    - Overall survival
    - To assess the safety and tolerability of lapatinib when administrated with both paclitaxel and trastuzumab compared to the combination of paclitaxel and trastuzumab. Toxicities will be recorded and graded according to the NCI - CTC criteria, version 4
    - Fact-B questionnaire
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Quality of Life
    Calidad de Vida
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned10
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA40
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Finland
    France
    Germany
    Greece
    Iceland
    Ireland
    Italy
    Netherlands
    Norway
    Poland
    Portugal
    Spain
    Switzerland
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    a maximum of 5 years after the last patient is enrolled into study
    5 años después de que la última paciente haya sido incluida en el estudio
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years7
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years7
    E.8.9.2In all countries concerned by the trial months6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 600
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 600
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state50
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 550
    F.4.2.2In the whole clinical trial 600
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The patients will be followed up every 3 months for the first two years.

    After completion of 2 years of follow-up all patients should be followed every 3 months (12 weeks) for survival until death or until a maximum of 5 years after the last patient is enrolled into study, whichever comes first.
    Se realizará seguimiento de las pacientes cada 3 meses durante los primeros dos años.

    Tras la finalización de los 2 primeros años de seguimiento, se las seguirá cada 3 meses (12 semanas) para evaluar la supervivencia, hasta el fallecimiento o hasta un máximo de 5 años después de que la última paciente haya sido incluida en el estudio, lo que suceda primero.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-02-18
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-02-08
    P. End of Trial
    P.End of Trial StatusTemporarily Halted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 07:59:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA